Substituted bicyclic HCV inhibitors

A compound having formula I:

• wherein:
• L1 and L2 are either linked or not linked, when not linked, L1 and L2 are independently H or lower alkyl (containing 1 to 4 carbons) moieties;
• when linked, L1-L2 are independently —CH2C(O)—, —C(O)—, —(CH2CH2—O—CH2CH2)p— wherein p is independently 1, 2 or 3, or lower alkyl (containing 1 to 4 carbons) moieties;
• D is O;
• m and n are independently 0, 1, 2, 3 or 4 and m and n may not be both 0;
• each Ra is independently selected from the group consisting of —CN, —NO2, halogen, C1 to C12 alkyl, C1 to C12 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino;
• each r is independently 0, 1, 2 or 3;
• W and W′ are each independently selected from the group consisting of
• wherein:
• X1 is CH2, NH, O or S,
• Y1, Y2 and Z1 are each independently CH or N,
• X2 is NH, O or S,
• W and W′ are each independently optionally substituted with one or more substituents selected from the group consisting of —CN, —NO2, halogen, C1 to C12 alkyl, C1 to C12 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino, and
• W and W′ attached to the central biphenyl moiety can have the following substitution patterns:
• wherein,
• the biphenyl moiety can be substituted with 0-4 nitrogen atom(s);
• and
• each Rc, Rd, Re and Rf is independently selected from the group consisting of:
• hydrogen, C1 to C8 alkyl, C1 to C8 heteroalkyl, aralkyl and a 4- to 8-membered ring which may be cycloalkyl, heterocycle, heteroaryl or aryl, wherein,
• each hetero atom, if present, is independently N, O or S,
• each of Rc, Rd, Re and Rf may optionally be substituted by C1 to C8 alkyl, C1 to C8 heteroalkyl, aralkyl, or a 4- to 8-membered ring which may be cycloalkyl, heterocycle, heteroaryl or aryl and wherein each heteroatom, if present, is independently N, O or S,
• Rc and Rd are optionally joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 5-membered heterocycle or heteroaryl ring, and
• Re and Rf are optionally joined to form a 4- to 8-membered heterocycle which is optionally fused to another 3- to 5-membered heterocycle or heteroaryl ring;
• Y and Y′ are each independently carbon or nitrogen;
• and
• Z and Z′ are independently selected from the group consisting of hydrogen, C1 to C8 alkyl, C1 to C8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, 1-3 amino acids, —[U—(CR42)t—NR5—C(R42)t]u—U—(CR42)t—NR7—(CR42)t—R8, —U—(CR42)t—R8, and —[U—(CR42)t—NR5—(CR42)t]u—U—(CR42)t—O—(CR42)t—R8, wherein,
• U is selected from the group consisting of —C(O)—, —C(S)— and —S(O)2—,
• each R4, R5 and R7 is independently selected from the group consisting of hydrogen, C1 to C8 alkyl, C1 to C8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl,
• R8 is selected from the group consisting of hydrogen, C1 to C8 alkyl, C1 to C8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, —C(O)—R81, —C(S)—R81, —C(O)—O—R81, —C(O)—N—R812, —S(O)2—R81 and —S(O)2—N—R812, wherein each R81 is independently chosen from the group consisting of hydrogen, C1 to C8 alkyl, C1 to C8 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl and aralkyl,
• optionally, R7 and R8 together form a 4-7 membered ring,
• each t is independently 0, 1, 2, 3, or 4, and
• u is 0, 1, or 2.